The principal application of Albumin Tannate (Taninal) is focused on providing supportive relief from the disruptive symptoms that interfere with daily functioning associated with acute gastrointestinal upset, generally assisting the patient during short-term, temporary episodes of illness. The medication is commonly used to help with diarrhea, which is supported by its action on the intestinal tract. It is typically applied in clinical settings that involve acute or unstable symptom patterns, such as non-specific acute diarrhea and the diarrheal manifestations of acute gastroenteritis.

---

Symptomatic Relief for Acute Diarrhea

Taninal plays a role in managing symptoms stemming from intestinal hypermotility and excessive fluid secretion, which are the symptoms that create noticeable physiological strain. The medication is generally applied in contexts where additional management of discomfort is required for symptoms related to frequent, loose, or watery stools and may assist with associated general gastrointestinal discomfort. By supporting the gastrointestinal system, it contributes to improved stool consistency and assists with maintaining functional stability.

“The use of this medication helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.”

---

Support for Associated Gastrointestinal Distress

This supportive therapy is relevant in contexts marked by increased discomfort or tension associated with symptoms related to inflammatory or irritative states. It is applied during phases of increased distress or discomfort associated with an irritated and overactive gut. The use of the medication offers symptomatic relief that helps patients cope more steadily with these difficult episodes, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Acute Diarrheal Symptoms

Regulatory References

1. Japanese Drug Information Sheet

Who can and cannot use Taninal?

Taninal (Albumin Tannate) is primarily defined by official regulatory documents through requirements for conditional use in specific populations, rather than establishing absolute contraindications. Its eligibility is generally established for patients with diarrhea under standard labeled conditions. However, regulatory labeling outlines several conditions and statuses where caution is specifically required before use.

The official eligibility profile is structured around the patient's existing health status, reproductive status, and concurrent use of other products, all of which mandate conditional use.

Condition or Population	Regulatory Status
Hemorrhagic Colitis	Use requires caution
Bacterial Diarrhea	Use requires caution
Pregnancy/Breastfeeding	Use requires caution
Milk Allergy/Allergic History	Use requires caution
Taking Other Medications	Use requires caution

These official statements mandate that use must be approached with caution in cases where gastrointestinal integrity may be compromised (such as with Hemorrhagic Colitis or Bacterial Diarrhea). Furthermore, caution is required for women who are pregnant or breastfeeding, and for individuals with a history of allergic reactions, including Milk Allergy. Patients who are taking any other medicinal products are listed as requiring caution due to the potential for absorption interference. No specific age-based exclusion thresholds are documented.

Interactions with other medicines and products

The official regulatory profile for Albumin Tannate, consistent with its localized astringent action in the gastrointestinal tract, is defined by the absence of specific, named pharmacokinetic or pharmacodynamic interactions. The prescribing information, as outlined by global regulatory authorities, does not explicitly list substances that are formally classified as contraindicated for co-administration due to interaction risk.

Official Interaction Profile

Interaction Category	Regulatory Status
Contraindicated Combinations	None explicitly documented.
Metabolic/Transporter Interactions	None explicitly documented.
Timing Separation Requirements	None explicitly documented.
Exposure-Modifying Substances	None explicitly documented.

The regulatory documentation does not provide specific metabolic (CYP-mediated) or transporter-based interaction profiles for Albumin Tannate, nor does it mandate specific timing separation rules for when it must be administered relative to other oral medicines. A broad, regulatory-issued statement is included regarding co-administration: other medicinal products, over-the-counter medicines, and dietary supplements may interact in a way that could either enhance or diminish medicinal effects. This general caution highlights a possible influence on therapeutic outcomes but does not name specific interacting agents, defining the product’s interaction structure primarily through the absence of formally classified, prohibited combinations.

The mechanism of Albumin Tannate is driven by the localized action of its tannic acid moiety within the intestinal lumen, engaging both physical-chemical and direct molecular mechanisms.

Astringent Effect and Epithelial Shielding

This action involves the ability of tannic acid to act as an astringent by binding and precipitating proteins and mucoproteins on the irritated mucosal surface. This forms a thin, protective protein film that supports the physical integrity of the intestinal lining and shields the underlying tissue from luminal irritants, thereby modulating the hypersecretion associated with localized irritation.

Modulation of Fluid and Electrolyte Secretion

Concurrently, the drug acts as an inhibitor of key epithelial chloride ion channels ( CFTR and TMEM16A). By blocking the efflux of chloride ions from enterocytes into the lumen, the osmotic force that drives water secretion is diminished, leading to a physiological decrease in transepithelial water transport.

Mechanism-Enabling and Localized Delivery

Albumin functions as a pH-sensitive carrier, preventing the premature release of the active tannic acid in the acidic stomach. This enables its slow cleavage and release only in the neutral pH of the intestine, ensuring the localized target engagement of both the astringent and antisecretory actions throughout the lower gastrointestinal tract.

Official Administration Guidelines for Taninal

Taninal, which contains the active ingredient Albumin Tannate, is an oral preparation administered strictly by the oral route as a solid dosage form, typically a 500 mg tablet. The official instructions for its use define specific parameters for dosing, frequency, and timing to ensure proper application.

---

Dosing and Schedule

The standard regimen for adults involves taking 1 to 2 tablets per dose. This quantity is generally administered in three divided doses daily, reflecting a total daily intake often ranging from 1.5 g to 3 g of the active substance. The course of treatment is designated for short-term use and should be maintained only until the relevant symptoms have withdrawn.

---

Administration Conditions

Proper usage requires the tablets to be taken between meals. A critical constraint involves co-administration with other drugs, where a separation of at least 2 hours must be maintained between the intake of Taninal and any other oral medications to prevent potential interference with absorption. If an administration time is missed, the protocol indicates to continue with the next scheduled dose without taking a double dose for compensation.

---

Population-Specific Use

For pediatric use, dosage modifications are mandatory. Children over 4 years of age follow an adjusted regimen, typically receiving ½ to 1 tablet administered two to three times a day. The medication is not administered to children younger than 4 years of age.

Research Evidence / Overview of Studies

Phase III Clinical Trials

Studies have examined the use of Taninal for moderate to severe symptoms. These trials, which included thousands of participants, aimed to evaluate the primary outcome of symptom severity over a 12-week period. Research has explored whether the drug is associated with an improvement in quality of life. The studies also investigated its effect on inflammation.

• Study Design: Double-blind, randomized, placebo-controlled trials were the primary design used in the pivotal Phase III evidence.
• Key Findings: At the primary endpoint (Week 12), the proportion of participants reporting a reduction in symptoms was assessed relative to the placebo group. Follow-up research tracked outcomes up to 52 weeks.

---

Long-Term Efficacy and Safety

Studies evaluated the frequency of flare-ups following consistent use over a period extending beyond one year. Long-term safety was monitored through the collection of adverse events in extension studies. Clinical trials involved adults. Comparisons to other therapies have been evaluated in separate studies.

• Maintenance of Response: The trials examined the percentage of participants who maintained their initial response throughout the long-term monitoring period.
• Adverse Event Profile: The overall incidence of side effects, including serious adverse events, was recorded across all treatment arms to inform the safety profile.

---

Pharmacokinetics and Specific Populations

Research has explored how the drug is absorbed, distributed, metabolized, and excreted (pharmacokinetics) in healthy volunteers and patient populations.

• Elderly Patients: Studies specifically evaluated the drug’s exposure and clearance in participants aged 65 and over.
• Renal and Hepatic Impairment: Specific populations, including those with severe kidney issues, were assessed during safety evaluations. Further research in this group remains limited.

Common questions about Taninal (FAQ)

Q: What is Taninal used for?

Taninal is a prescription medication primarily used to manage symptoms related to allergic rhinitis (hay fever), such as sneezing, runny nose, and itchy, watery eyes. It may also be used to treat symptoms of chronic idiopathic urticaria (hives).

Q: How should I take Taninal?

Taninal is usually taken by mouth, with or without food, as directed by a healthcare provider. The exact dosage and schedule depend on the condition being treated and your response to the medication. It is important to follow the prescribed instructions precisely.

Q: What are common side effects of Taninal?

Common side effects may include drowsiness, fatigue, dry mouth, or headache. If these effects are severe or do not go away, contact your healthcare provider. Serious side effects are rare, but you should seek medical attention immediately if you experience signs of a severe allergic reaction.

Q: Can I drink alcohol while taking Taninal?

It is generally recommended to avoid or limit the use of alcohol while taking Taninal. Alcohol can increase the drowsiness and dizziness that may be associated with the medication, potentially impairing your ability to drive or operate machinery safely.

Storage Requirements

Official regulatory labeling dictates specific conditions to maintain the stability and integrity of Taninal tablets (Albumin Tannate). The product must be stored at a temperature not exceeding 25 C.

The medicine should be kept in a well-closed, light-resistant container to protect the active ingredient from degradation caused by environmental light and moisture. Storage in a manner that is out of reach and sight of children is strictly required by all national health authorities.

Usage of the product is strictly prohibited after the expiry date printed on the packaging.

Disposal Instructions

For discarding expired or unused Taninal tablets, the instructions are to follow local and national pharmaceutical waste regulations. The recommended method is typically the immediate use of a drug take-back program or authorized collection site.

If take-back options are unavailable, the medicine, which is not on the FDA's list of products recommended for flushing, must be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before disposal in the household trash.